CN101119725B - 化学趋化因子受体拮抗剂的固体形式和其使用方法 - Google Patents

化学趋化因子受体拮抗剂的固体形式和其使用方法 Download PDF

Info

Publication number
CN101119725B
CN101119725B CN2005800481176A CN200580048117A CN101119725B CN 101119725 B CN101119725 B CN 101119725B CN 2005800481176 A CN2005800481176 A CN 2005800481176A CN 200580048117 A CN200580048117 A CN 200580048117A CN 101119725 B CN101119725 B CN 101119725B
Authority
CN
China
Prior art keywords
citrate
weight
citrate salt
sample
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800481176A
Other languages
English (en)
Chinese (zh)
Other versions
CN101119725A (zh
Inventor
查理·尼维斯
奥瑞利亚·谢瓦利埃
帕斯卡·比洛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN101119725A publication Critical patent/CN101119725A/zh
Application granted granted Critical
Publication of CN101119725B publication Critical patent/CN101119725B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2005800481176A 2004-12-17 2005-12-19 化学趋化因子受体拮抗剂的固体形式和其使用方法 Expired - Fee Related CN101119725B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63721304P 2004-12-17 2004-12-17
US60/637,213 2004-12-17
PCT/US2005/045915 WO2006066200A2 (en) 2004-12-17 2005-12-19 Solid forms of a chemokine receptor antagonist and methods of use thereof

Publications (2)

Publication Number Publication Date
CN101119725A CN101119725A (zh) 2008-02-06
CN101119725B true CN101119725B (zh) 2013-04-17

Family

ID=36588631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800481176A Expired - Fee Related CN101119725B (zh) 2004-12-17 2005-12-19 化学趋化因子受体拮抗剂的固体形式和其使用方法

Country Status (9)

Country Link
US (2) US7960549B2 (cg-RX-API-DMAC10.html)
EP (1) EP1841429B1 (cg-RX-API-DMAC10.html)
JP (3) JP5308030B2 (cg-RX-API-DMAC10.html)
CN (1) CN101119725B (cg-RX-API-DMAC10.html)
AT (1) ATE553761T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005316340B2 (cg-RX-API-DMAC10.html)
CA (1) CA2590157C (cg-RX-API-DMAC10.html)
ES (1) ES2386029T3 (cg-RX-API-DMAC10.html)
WO (1) WO2006066200A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020390992A1 (en) * 2019-11-29 2022-06-09 Sunshine Lake Pharma Co., Ltd. Crystalline form of nitrogen-containing tricyclic compound and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1999037619A1 (en) 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DK1049700T3 (da) 1998-01-21 2006-02-20 Millennium Pharm Inc Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
HU228314B1 (hu) 1998-09-04 2013-03-28 Millennium Pharmaceuticals Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EP1109815A1 (en) 1998-09-04 2001-06-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU6503900A (en) 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
US20120065223A1 (en) 2012-03-15
EP1841429B1 (en) 2012-04-18
WO2006066200A3 (en) 2007-01-25
JP5308030B2 (ja) 2013-10-09
US7960549B2 (en) 2011-06-14
AU2005316340B2 (en) 2012-01-19
HK1109350A1 (en) 2008-06-06
AU2005316340A1 (en) 2006-06-22
JP2015057445A (ja) 2015-03-26
CA2590157C (en) 2013-11-05
ATE553761T1 (de) 2012-05-15
JP2008524253A (ja) 2008-07-10
CN101119725A (zh) 2008-02-06
WO2006066200A2 (en) 2006-06-22
JP2012211197A (ja) 2012-11-01
US20070010545A1 (en) 2007-01-11
US8481737B2 (en) 2013-07-09
EP1841429A2 (en) 2007-10-10
CA2590157A1 (en) 2006-06-22
ES2386029T3 (es) 2012-08-07

Similar Documents

Publication Publication Date Title
CN104736526B (zh) 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
JP5134552B2 (ja) ジヒドロプテリジノン誘導体の三塩酸塩形及び調製方法
US6242460B1 (en) Zolpidem salt forms
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
EP1939176A1 (en) Salts of Tegaserod
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
JP2023502011A (ja) レバムロジピンベシル酸塩水和物含有組成物及びその調製方法
US20040063782A1 (en) Bicalutamide forms
US9095585B2 (en) Bioavailable compositions of amorphous piperidinyl compounds
US9682988B2 (en) Solid salt form of α-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
JP5847567B2 (ja) 活性医薬成分の結晶形態
US8481737B2 (en) Solid forms of a chemokine receptor antagonist and methods of use thereof
TWI532734B (zh) Crystallization of Alesartan Ester and its preparation method and pharmaceutical composition containing the same
WO2000058310A1 (en) Zolpidem salts
US20040038985A1 (en) Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride
CN112851640B (zh) 嘧啶苯甲酰胺化合物的硫酸盐及其用途
HK1109350B (en) Solid forms of a chemokine receptor antagonist and methods of use thereof
HK40116055A (en) Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
WO2024153165A1 (zh) 一种抗抑郁化合物的盐、其制备方法、包含其的药物组合物及其用途
HK40079890A (en) Compositions and methods related to picolinylpiperidine 5-ht1f agonists
CN119654328A (zh) (S)-7-氧杂-2-氮杂-螺[4.5]癸烷-2-甲酸[7-(3,6-二氢-2H-吡喃-4-基)-4-甲氧基-噻唑并[4,5-c]吡啶-2-基]-酰胺的新型结晶形式及其共晶形式
KR20080106232A (ko) 베시피르딘 클로하이드레이트의 결정형, 그 제조 방법 및 용도
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
CN111518092A (zh) 利伐沙班乙酸溶剂合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130417

Termination date: 20191219

CF01 Termination of patent right due to non-payment of annual fee